Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Free Cash Flow: 2010-2025

Historic Free Cash Flow for Iovance Biotherapeutics (IOVA) over the last 9 years, with Sep 2025 value amounting to -$89.5 million.

  • Iovance Biotherapeutics' Free Cash Flow fell 46.17% to -$89.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$351.8 million, marking a year-over-year increase of 5.94%. This contributed to the annual value of -$364.1 million for FY2024, which is 5.22% up from last year.
  • As of Q3 2025, Iovance Biotherapeutics' Free Cash Flow stood at -$89.5 million, which was down 19.55% from -$74.9 million recorded in Q2 2025.
  • Over the past 5 years, Iovance Biotherapeutics' Free Cash Flow peaked at -$61.3 million during Q3 2024, and registered a low of -$126.5 million during Q1 2024.
  • Over the past 3 years, Iovance Biotherapeutics' median Free Cash Flow value was -$89.5 million (recorded in 2025), while the average stood at -$93.0 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first surged by 30.12% in 2024, then slumped by 46.17% in 2025.
  • Over the past 3 years, Iovance Biotherapeutics' Free Cash Flow (Quarterly) stood at -$87.5 million in 2023, then grew by 11.44% to -$77.5 million in 2024, then plummeted by 46.17% to -$89.5 million in 2025.
  • Its Free Cash Flow was -$89.5 million in Q3 2025, compared to -$74.9 million in Q2 2025 and -$109.9 million in Q1 2025.